By Dr Heloisa Zaccaron Milioli

Journal articles

Alexandrou S; Lee CS; Fernandez KJ; Wiharja CE; Eshraghi L; Reeves J; Reed DA; Portman N; Phan Z; Milioli HH; Nikolic I; Cadell AL; Croucher DR; Simpson KJ; Lim E; Hickey TE; Millar EKA; Alves CL; Ditzel HJ; Caldon CE, 2025, 'JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer', Journal of Experimental and Clinical Cancer Research, 44, http://dx.doi.org/10.1186/s13046-025-03466-9

Chaffer CL; Milioli HH; San Juan BP; Dear RF; Liu JJ, 2025, 'Abstract 4744: State-gating cancer to prevent chemotherapy-resistance', Cancer Research, 85, pp. 4744 - 4744, http://dx.doi.org/10.1158/1538-7445.am2025-4744

Gemma C; Lai CF; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin LA; Lim E; Charles Coombes R; Pruneri G; Buluwela L; Ali S, 2024, 'Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer', Cancer Research, 84, pp. 4283 - 4297, http://dx.doi.org/10.1158/0008-5472.CAN-24-0013

Sahoo S; Ramu S; Nair MG; Pillai M; San Juan BP; Milioli HZ; Mandal S; Naidu CM; Mavatkar AD; Subramaniam H; Neogi AG; Chaffer CL; Prabhu JS; Somarelli JA; Jolly MK, 2024, 'Increased prevalence of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer', Iscience, 27, http://dx.doi.org/10.1016/j.isci.2024.110116

Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia KM; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Chen W; Pidsley R; Qu W; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, 2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512, http://dx.doi.org/10.1038/s41594-023-01181-7

McKinnon JC; Milioli HH; Purcell CA; Chaffer CL; Wadie B; Alexandrov T; Mitchell TW; Ellis SR, 2023, 'Enhancing metabolite coverage in MALDI-MSI using laser post-ionisation (MALDI-2)', Analytical Methods, 15, pp. 4311 - 4320, http://dx.doi.org/10.1039/d3ay01046e

Shehadeh-Tout F; Milioli HH; Roslan S; Jansson PJ; Dharmasivam M; Graham D; Anderson R; Wijesinghe T; Azad MG; Richardson DR; Kovacevic Z, 2023, 'Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer', Pharmacological Research, 193, pp. 106806, http://dx.doi.org/10.1016/j.phrs.2023.106806

Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7

Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Bustamante S; Sabaretnam T; Moscato P; Lim CK; Guillemin GJ, 2020, 'Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression', Breast Cancer Research, 22, http://dx.doi.org/10.1186/s13058-020-01351-1

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2

Milioli HH; Alexandrou S; Lim E; Caldon CE, 2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine Related Cancer, 27, pp. R93 - R112, http://dx.doi.org/10.1530/ERC-19-0501

Chia KM; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E, 2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine Related Cancer, 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333

Milioli HH; Tishchenko I; Riveros C; Berretta R; Moscato P, 2017, 'Basal-like breast cancer: molecular profiles, clinical features and survival outcomes', BMC Medical Genomics, 10, http://dx.doi.org/10.1186/s12920-017-0250-9

Tishchenko I; Milioli HH; Riveros C; Moscato P, 2016, 'Extensive transcriptomic and genomic analysis provides new insights about luminal breast cancers', Plos One, 11, http://dx.doi.org/10.1371/journal.pone.0158259

Milioli HH, 2016, 'Life as an early career researcher: Interview with Heloisa Helena Milioli', Future Science Oa, 2, http://dx.doi.org/10.4155/fsoa-2016-0033

Oliveira NCS; Gomig THB; Milioli HH; Cordeiro F; Costa GG; Urban CA; Lima RS; Cavalli IJ; Ribeiro EMSF, 2016, 'Comparative proteomic analysis of ductal and lobular invasive breast carcinoma', Genetics and Molecular Research, 15, http://dx.doi.org/10.4238/gmr.15027701

Milioli HH; Vimieiro R; Tishchenko I; Riveros C; Berretta R; Moscato P, 2016, 'Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset', Biodata Mining, 9, http://dx.doi.org/10.1186/s13040-015-0078-9

Milioli HH; Vimieiro R; Riveros C; Tishchenko I; Berretta R; Moscato P, 2015, 'The discovery of novel biomarkers improves breast cancer intrinsic subtype prediction and reconciles the labels in the METABRIC data set', Plos One, 10, http://dx.doi.org/10.1371/journal.pone.0129711

Milioli HH; Tishchenko I; Riveros C; Sakoff J; Berretta R; Moscato P, 2015, 'Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making', Annals of Oncology, 26, pp. iii31, http://dx.doi.org/10.1093/annonc/mdv121.08

Milioli HH; Tishchenko I; Riveros C; Berretta R; Moscato P, 2015, 'Molecular classification of basal-like breast cancer subtypes based on predictive survival markers', Annals of Oncology, 26, pp. iii15, http://dx.doi.org/10.1093/annonc/mdv117.11

Milioli HH; Sousa KS; Kaviski R; Oliveira NCDS; De Andrade Urban C; De Lima RS; Cavalli IJ; De Souza Fonseca Ribeiro EM, 2015, 'Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion', Cancer Genomics and Proteomics, 12, pp. 89 - 101

Back to profile page